Compare FedEx Corporation (FDX) vs Hims and Hers Health Inc (HIMS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
FedEx Corporation vs Hims and Hers Health Inc — how do they compare? FedEx Corporation trades at $316.19 (market cap $74.78B), while Hims and Hers Health Inc trades at $34.63 (market cap $8.60B). The key difference: FedEx Corporation is far larger — about 8.7× Hims and Hers Health Inc's market cap, and FedEx Corporation pays a 1.56% dividend while Hims and Hers Health Inc pays none. Which is the better fit depends on your goals.
| FDX | HIMS | |
|---|---|---|
Market Cap | $74.78B | $8.60B |
Sector | Industrials | Health |
52-Week High | $338.75 | $66.18 |
52-Week Low | $174.81 | $14.52 |
Enterprise Value | $104.42B | $8.98B |
Dividend Yield | 1.56% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FedEx (FDX) trades at $316.24, up 0.82% on the day, with a bearish technical signal despite recent earnings beats. The company shows steady revenue near $88B and net income of $4.09B in 2025, supported by a P/E of 16.9 and strong analyst consensus. Recent developments include the sale of FedEx Supply Chain for $1.4B and a $4.15B debt tender offer, enhancing financial flexibility.
The outlook is mixed: cost-cutting initiatives and strategic divestitures provide upside, but competitive pressures from Amazon and soft shipping demand pose risks. With 57% of analysts rating it Buy and a $360.27 price target, the stock offers potential appreciation if margin recovery aligns with guidance, though execution remains key.
Hims & Hers Health trades at $34.78, down 1.05% today, with a mixed technical picture showing bullish moving averages but neutral oscillators. Fundamentally, the company reported $2.35B revenue in 2025 but faces profitability challenges with a negative net income margin of -0.56% and elevated valuation ratios including a P/E of 57.14. Recent news highlights expansion in weight-loss therapies and international markets, with Q2 2026 earnings due August 10, 2026.
The outlook remains cautiously optimistic with analyst consensus at Buy (35%) and a $33.57 price target near current levels. Key opportunities include GLP-1 therapy growth and subscriber additions, while risks involve profitability pressures, competitive threats, and reliance on regulatory approvals. The stock's performance hinges on execution in high-margin segments and cost management amid expansion.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About FedEx Corporation
FedEx pioneered overnight delivery in 1973 and remains the world's largest express package provider. In its fiscal 2020 (ended May 2020), FedEx derived 51% of revenue from its express division, 33% from ground, and 10% from freight, its asset-based less-than-truckload shipping segment. The remainder comes from other services, including FedEx Office, which provides document production/shipping, and FedEx Logistics, which provides global forwarding. FedEx acquired Dutch parcel delivery firm TNT Express in 2016. TNT was previously the fourth-largest global parcel delivery provider.
Read more on FDX →About Hims and Hers Health Inc
Hims & Hers is a multi-specialty telehealth platform that provides personalized health and wellness products. It offers access to medical providers and treatments for hair loss, sexual health, and skincare.
Read more on HIMS →
